Ocuphire Pharma Investor Update

RM 17 Primary Endpoint: 58% of Subjects' Study Eye Returned to Baseline at 90 Min Nyxol Statistically Better Than Placebo Starting At 1 Hour And All Subsequent Timepoints Percent of Subjects (%) 100% 80% 60% 40% 20% 0% 4% 4% 0.5 MIRA-3 Phase 3 Trial Percent of Subjects Returning to ≤ 0.2 mm of Baseline Pupil Diameter Study Eye (mITT) p<0.0001 2% 42% 1 p<0.0001 58% 6% p<0.0001 7% 66% p<0.0001 2 14% 79% p<0.0001 Source: MIRA-3 Table 14.2.1.1 (mITT). Data include all three mydriatics (Phenylephrine, Tropicamide, Paremyd). 17% 1.5 3 4 Time Post-Treatment with Nyxol/Placebo (Hours) Placebo (n=124) Nyxol (n=244) 86% p<0.0001 36% 91% 6 p<0.0001 72% 89% 24 Ocuphire PHARMA

View entire presentation